ROCHESTER, Mich., Oct. 05, 2016 -- OptimizeRx Corp. (OTCQB:OPRX), a health technology software company whose premier content-delivery platform enables pharmaceutical companies to provide point of care patient-care services, has acquired all of the LogRx inventory for the remainder of 2016 and 2017 from Allscripts Healthcare, LLC (NASDAQ:MDRX), a global leader in healthcare information technology solutions. Under this expanded partnership, OptimizeRx will sell the Allscripts LogRx messaging solution.
“This expanded partnership with Allscripts extends our point of care solutions that we can bring to the medical community,” said William Febbo, CEO of OptimizeRx. “The LogRx product strongly complements our core financial messaging (eCoupon) product, and it allows us to continue to increase and diversify our revenue base. We expect this expanded partnership to have a material impact on revenue in 2017 and beyond, and we are pleased with this continued validation of our value added solutions.”
Lynn O’Connor Vos, CEO of ghg, a subsidiary of WPP, commented: “Given OptimizeRx’s continued integration into the pharmaceutical companies within WPP, this allows us to bring additional value to our collective clients as the lead aggregator of services at point of care. The continued decline of accessibility of sales representatives to Health Care Providers makes the point of care delivery of messaging critical to improving outcomes for the patients.”
About Allscripts
Allscripts (NASDAQ:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.
About OptimizeRx Corp
OptimizeRx Corporation (OTCQB:OPRX) provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand awareness, access and adherence to their medications.
The company’s core product replaces drug samples with electronic trial vouchers and copay coupon savings that are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading electronic health record (EHR) platforms in the country, including Allscripts, Quest Diagnostics, Practice Fusion and other EHRs to reach over 250,000 healthcare providers. In turn, OptimizeRx promotes patient savings and support from the world’s largest pharmaceutical companies, including Pfizer, Lilly, Novartis, AstraZeneca and many others. For more information, please go to www.optimizerxcorp.com.
Company Contact:
OptimizeRx
Doug Baker
[email protected]
248-651-6568 x807
Investor Relations Contact:
Liolios Group
Ron Both, Senior Managing Director
[email protected]
949-574-3860


UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
First Western Ship Transits Strait of Hormuz Since Iran War Began
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 



